Previous studies have shown that TZD can increase the serum level of adiponectin, which is known to be associated with an increased risk of MetS and CVD.[41] Our results suggest the need for additional assessments of risk factors for T2DM, CVD, and MetS in clinical studies of TZD treatment for NAFLD or NASH. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.